DRKS00024559
Completed
未知
Incremental infusion of atrial natriuretic peptide suppresses leptin secretion in healthy men.
Deutsches Zentrum für Luft- und Raumfahrt (DLR)Institut für Luft- und Raumfahrtmedizin0 sites17 target enrollmentJune 21, 2021
ConditionsHyperleptinemia
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Hyperleptinemia
- Sponsor
- Deutsches Zentrum für Luft- und Raumfahrt (DLR)Institut für Luft- und Raumfahrtmedizin
- Enrollment
- 17
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •BMI 20\-25 kg/m2
- •No medication
Exclusion Criteria
- •BMI \< 20 or \> 25 kg/m2
- •Any medication
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
ow dose atrial natriuretic peptide provides effective renal protection from acute kidney injury after aortic arch surgery: a randomised controlled trialacute kidney injuryJPRN-UMIN000011650Kawasaki Saiwai Hospital43
Completed
Not Applicable
Phase 1 study of human atrial natriuretic peptide during perioperative period for completely resected colorectal cancerJPRN-UMIN000025877Osaka University Graduate School of Medicine5
Completed
Phase 2
Human atrial natriuretic peptide during perioperative period for completely resected non-small cell lung cancer: a multicentre, open-label, randomised controlled trialJPRN-UMIN000018480ational Cerebral and Cardiovascular Center332
Completed
Not Applicable
Efficacy of human atrial natriuretic peptide for the patients with severe sepsis; Impact on prevention against acute kidney injurySevere sepsisJPRN-UMIN000003821Tosei General Hospital60
Completed
Not Applicable
sing Brain-Natriuretic Peptide (blood test for heart failure) and the San Francisco Syncope Rule to reduce hospital admissions for fainting.ACTRN12612000489897Karen Shakespeare450